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Abstract
During times of stress, systemic pro-inflammatory cytokine levels are increased, which
may prevent optimal growth and development of muscle and/or induce muscle atrophy. Proinflammatory cytokines can induce negative responses in muscle by altering the balance of
protein synthesis and degradation in established myofibers, or by influencing the proliferation
and differentiation of myoblasts. Interleukin-1 beta (IL-1β) is a pro-inflammatory cytokine
involved in stress and disease responses, but little is known about how IL-1β affects myoblast
function. We hypothesized that IL-1β would decrease myoblast proliferation and/or
differentiation. To test this hypothesis, C2C12 mouse myoblasts were treated with 0.1 ng/mL or
1.0 ng/mL of IL-1β, or carrier only (control). To determine proliferation rate, myoblasts were
plated at 2.6x103 cells/cm2 and cultured for 48 h in the presence or absence of IL-1β. Cells were
pulsed with bromodeoxyuridine (BrdU), fixed, and immunostained. The number of BrdU
positive cells was quantified as a percent of total nuclei (identified by Hoescht 33342). To
determine if IL-1β affected fusion, myoblasts were plated at 2.0x104 cells/cm2 in growth media
for 48 h at which time media was changed into differentiation media supplemented with 0.1
ng/mL or 1.0 ng/mL of IL-1β, or carrier only. Cells were immunostained with myosin heavy
chain (MyHC) and Hoescht 33342. Fusion index was determined by quantifying the number of
nuclei within multinucleated myotubes divided by total nuclei. Finally, to determine the effect of
IL-1β on myotube size, myoblasts were cultured for 48 h in growth media and 48 h in
differentiation media. Cells were cultured for an additional 48 h in the presence or absence of
IL-1β, fixed and immunostained for MyHC. Myotube diameter and fusion index were
quantified. All data was analyzed using ANOVA in GraphPad Prism followed by Tukey’s test
for multiple comparisons. There were no significant effects of IL-1β on proliferation or fiber
diameter (P ≥ 0.05). However, fusion was decreased 13.5% in myoblasts treated with 1.0 ng/mL
2

of IL-1β (P ≤ 0.05). In conclusion, IL-1β decreases myoblast fusion, but does not affect
proliferation or fiber diameter. These results suggest that IL-1β may contribute to poor muscle
growth by decreasing fusion of myoblasts into existing myofibers, preventing optimal
hypertrophy.
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Review of Literature
Introduction
The effects of pro- and anti-inflammatory cytokines are affected by four variables: the
timing of cytokine release, the other hormones present when the cytokines are released, the
number of available receptors on the cell, and tissue responsiveness to each cytokine (Opal and
DePalo, 1999). However, pro- and anti-inflammatory cytokines do not work independently; they
interact with each other creating a coordinated level of control. Further, anti-inflammatory
cytokines influence the secretion of pro-inflammatory cytokines throughout the body (Barton et
al., 1996). There are distinctions between the mechanisms of each different cytokine, in that proinflammatory cytokines inhibit the immune response and anti-inflammatory cytokines repress the
immune response. Interleukins (IL) are a subset of cytokines secreted from leukocytes with
either pro- or anti-inflammatory characteristics (Dinarello and Mier, 1986). For example, IL-1
and tumor necrosis factor (TNF)-α are examples of pro-inflammatory interleukins that can
induce negative responses in muscle by altering the balance of protein synthesis and degradation
or by influencing the proliferation and differentiation of myoblasts (Spate and Schulze, 2004).
Expression of IL-1 and TNFα is increased during times of stress such as changes in the
environment, disease, and transportation, and this can prevent optimal growth and development
of muscle. Interleukins have a wide variety of functions within the body and can induce protein
degradation, stimulate myoblast proliferation, and create inflammation (Spate and Schulze,
2004). Interleukin-1β is a pro-inflammatory interleukin involved with stress and disease
responses and is responsible, at least in part, for detrimental effects such as inflammation and
muscle atrophy in chronic diseases like cancer, chronic heart failure, and sepsis (Spate and
Schulze, 2004).
5

Pro-inflammatory cytokines
Pro-inflammatory cytokines are molecules that prompt and facilitate local catabolic
reactions which break down molecules and release energy, and this process can lead to muscle
atrophy and the breakdown of metabolic materials (Spate and Schulze, 2004). These proinflammatory cytokines can also act as local and/or systemic markers of inflammation because
the abnormalities created by these cytokines can be measured, and subsequent inflammation may
affect the entire body or a specific tissue (Spate and Schulze, 2004). For example, chronic heart
disease is associated with metabolic abnormalities which can lead to an increase in local
concentrations of pro-inflammatory cytokines due to stress, and this may ultimately lead to
skeletal muscle damage (Drexler et al., 1992). The metabolic abnormalities due to chronic
disease and increase in pro-inflammatory cytokines cause a decrease in muscle oxidative
capacity which leads to reduced muscle function (Drexler et al., 1992). It is not explicitly known
how these pro-inflammatory cytokines cause detrimental changes locally within the muscle, but
the interactions eventually lead to muscle atrophy (Spate and Schulze, 2004). Systemic
concentrations of these cytokines can also affect the total body during periods of chronic disease.
Although local and systemic concentrations may both be present in the same disease, having
elevated local concentrations of pro-inflammatory cytokines does not necessarily indicate there
will be elevated concentrations systemically as well (Spate and Schulze, 2004).

Interleukins
Interleukins, a group of pro- and anti-inflammatory cytokines, are products of
macrophages or T cells, and induce cell growth, differentiation, and activation of other T cells
(Mizel, 1989). Many different cell types, including macrophages, T cells, and cells within the
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bone marrow, produce a wide variety of ILs (Mizel, 1989). Interleukins have various functions
in the body and the potential to create a positive or negative effect on the tissue (Dinarello and
Mier, 1986). For example, IL-1 and IL-1β are pro-inflammatory, IL-10 is anti-inflammatory, and
IL-6 has both pro- and anti-inflammatory characteristics (Dinarello and Mier, 1986).
Interleukin-10 inhibits the inflammatory response and promotes healing in the body. In
men challenged with endotoxin, pre- or post-injection with IL-10 decreased the severity of
symptoms caused by the LPS endotoxin (Pajkrt et al., 1997). This decrease in symptoms
validates that IL-10 decreases the body’s response, preventing negative effects, and further
research could potentially show this is due to a decrease in immune response. Interleukin-10
works together with specific receptors to influence the immune system, thus achieving a specific
response within the cell that will act on the entire body (Opal and DePalo, 1999).
Interulekin-6 is an example of an interleukin that has both pro- and anti-inflammatory
characteristics. Barton et al. (1996) conducted an experiment that showed that IL-6 can have
anti-inflammatory characteristics by injecting mice with d-galactosamine, causing systemic
shock and ultimately the production of IL-6 within the body. Pretreatment with IL-6 antibodies,
inhibiting IL-6, increased mortality, while a pretreatment with IL-6 itself decreased mortality.
This showed that if IL-6 is present before disease consumes the body, there will be decreased
mortality. The effects of IL-6 on skeletal muscle was also studied by Kim et al. (2004), who
suggested that IL-6 has pro-inflammatory characteristics and causes a significant impairment of
insulin action in skeletal muscle. They found there was a decrease in whole body insulin
resistance in mice infused with an injection of 0.5µg of IL-6, which decreased the amount of
glucose the skeletal muscle took up. Therefore, this decrease in glucose uptake caused
significant impairment in the skeletal muscle such as a decrease in muscle glucose metabolism.
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However, it has also been shown that this cytokine can do the opposite to skeletal muscle. Meng
et al. (2014) showed that IL-6 is one of the factors that modulate muscle regeneration. RNF13
knockout mice had accelerated muscle regeneration which could be due to increase production of
IL-4/IL-6. Therefore, they concluded that IL-6 is facilitates satellite cell proliferation and
potential muscle regeneration after injury.

IL-1
Interleukin-1 is a pro-inflammatory cytokine, produced by phagocytic cells such as blood
monocytes and phagocytic cells that line organs (Dinarello and Mier, 1986). Cytokines
produced by these cells elicit systemic effects on organ systems throughout the body, beyond the
tissue from which they are produced. However, IL-1 can also have a local effect when it is
produced from specialized cells like B cells and large granular lymphocytes (Dinarello and Mier,
1986). In patients infected with a localized bacterial infection, monocytes and macrophages
within the tissue became active and released IL-1, resulting in pathological changes including
inflammation and fever (Dinarello and Mier, 1986). Additionally, inflammation in pigs resulted
in the production of IL-1 which stimulated the production of prostaglandin E2 (PGE2) from
fibroblasts and induced fever and inflammation throughout the body (Saklatvala et al., 1984).
Interleukin-1β is a form of IL-1 which produces catabolic effects on protein metabolism (Spate
and Schulze, 2004). This specific cytokine can trigger the local expression of nuclear factor
kappa B (NF-κB), a transcription factor resulting in the production of pro-inflammatory
cytokines, creating negative effects such as inflammation and reduction of muscle growth (Spate
and Schulze, 2004).
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Increased concentrations of these pro-inflammatory cytokines, especially IL-1β, cause
detrimental effects in many chronic diseases including cancer, chronic heart failure, diabetes
mellitus, and sepsis (Spate and Schulze, 2004). For example, during chronic heart failure, there
is an increase in IL-1β and a decrease in local expression of IGF-I (Schulze et al., 2003). In rats
with myocardial infarctions, pro-inflammatory cytokines induced muscle atrophy, which was
associated with a decrease in IGF-I production and an increase in IL-1β production from skeletal
muscle cells. Due to this increase in IL-1β and decrease in concentration of IGF-I, there was a
decrease in muscle cross-sectional area, which was expected because IGF-I plays a major role in
the growth and differentiation of cells and supporting the hypothesis that IL-1 and IL-1β cause
severe detrimental effects to muscle strength and to the body in periods of chronic disease.
Despite having opposite effects, both pro- and anti-inflammatory cytokines are
interrelated and can create a coordinated level of control. A specific anti-inflammatory cytokine
can inhibit the function of a pro-inflammatory cytokine by acting similarly to a pro-inflammatory
cytokine. Specific anti-inflammatory cytokines are able to bind to the same receptors as the
corresponding pro-inflammatory cytokine, but since they bind with even greater affinity, the proinflammatory cytokine cannot bind, and thus, cannot cause a negative effect (Opal and DePalo,
1999). For example, IL -1 receptor antagonist (IL-1ra) is a protein that is capable of inhibiting
IL-1 and IL-1β because it competitively binds to the same receptor as IL-1 and IL-1β (Opal and
DePalo, 1999). However, the newly bound IL-1ra fails to send signals throughout the cell
because it is not specific to the receptor and therefore, does not activate the cell. The accessory
protein IL-1 will not be produced and the negative effects on the immune system will be
inhibited, creating less of an effect on the body during a diseased state. Therefore, Opal and
Depalo (1999) hypothesized that this anti-inflammatory cytokine has the ability to act as an
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inhibitory factor to pro-inflammatory cytokines and could be an important factor to study the
effects and treatments for chronic disease. Although IL-1 and IL-1β create negative effects on
the body, IL-1ra can decrease the production and lessen the effect on the body by mimicking the
pro-inflammatory cytokine, binding to the receptor, and reducing the amount of receptors
available for IL-1 and IL-1β.

Pathway of IL-1β secretion
When the innate immune system senses invasion by different bacteria or infection, the
immune system is activated, starting the cascade of effects to produce pro-inflammatory
cytokines and promoting the inflammatory response (Weber et al., 2010b). First, the immune
system activates the NACHT, a leucine-rich repeat (LRR) and pyrin domain (PYD) -containing
protein 3 (NALP3) inflammasome pathway which plays a critical role in acute and chronic
inflammation and enhances the production of IL-1β during different diseases. A three protein
complex, the NALP3-inflammasome’s primary role is to increase inflammation. One of the
proteins that make up NALP3-inflammasome is caspase-1, which, once activated, processes the
precursor of IL-1β, regulating the release of its mature form. If capase-1 is mutated, there are
systemic increases in IL-1β because caspase-1 cannot regulate the concentrations of IL-1β in the
body.
Interleukin-1β is primarily produced by macrophages and monocytes, cells within the
innate immune system, and it can also be produced by epithelial cells, endothelial cells, and
fibroblasts (Weber et al., 2010a). This pro-inflammatory cytokine works in either a paracrine
manner, via cell to cell communication, or systemically through a protein secretion pathway.
Interleukin-1β works as a positive feedback promoter, inducing the expression of itself when
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concentrations rise within the body. IL-1β binds to the IL-1 receptor creating a ligand-induced
conformational change within the receptor. This facilitates recruitment of an accessory protein
which ultimately leads to the activation of transcription factors, nuclear factor kappaB (NF-κB)
and an activator protein. It also activates the c-Jun N-terminal kinase (JNK) pathway as well as
the nuclear p38 pathway. The JNK then phosphorylates proteins that are part of the activator
protein which ultimately increases the expression of IL-1, IL-6, and IL-8. Nuclear p38
phosphorylates splicing regulatory proteins, which destabilizes the mRNA to control the
production of IL-1 regulated transcripts, decreasing expression. Also, the binding of IL-1β to the
IL-1 receptor induces phosphorylation of heat shock proteins which are then used to induce IL-1
expression. In all, this binding increases the production of other pro-inflammatory cytokines as
well as the regulation and production of IL-1β.

Effects of IL-1β on skeletal muscle
Muscle inflammation is a major symptom of many diseases and can create lasting and
detrimental effects on the body. Skeletal muscle inflammation can be caused by many different
cytokines, including IL-1β. In animals with cancer, levels of IL-1β are increased in the blood
and this is linked with muscle atrophy (Spate and Schulze, 2004). Additionally, IL-1β is
associated with increased levels of myogenic transcription factors and an increase in the
expression of p38 kinase which resulted in early myogenesis and differentiation. Fibronectin and
integrin-β1, which modify extracellular matrix assembly and signaling, were also increased in
tumor bearing animals. Thus, due to a release of these factors, there was an early activation of
satellite cells and an increase in inflammatory cells that had migrated into the skeletal muscle.
Further, tumor bearing animals had decreased IGF binding protein 4 and 6 and an increase in
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IGF binding protein 5, which could potentially alter the concentrations of IGF within the blood.
Insulin-like growth factor is a critical hormone that is needed for skeletal muscle to proliferate
and differentiate, resulting in muscle growth. Additionally, in the presence of IGF-1, a low
concentration of IL-1β significantly suppressed protein synthesis, myogenin expression and
myoblast differentiation. It also impaired IGF-1 action within the muscle which decreased the
ability of IGF-1 to promote protein synthesis.
Additionally, Grundtman et al. (2007) found there was an increase in IL-1β in the
muscle in patients with polymyositis and dermatoyositis, inflammatory diseases that are
associated with muscle weakness and muscle fiber necrosis. In the muscle tissue from patients
with polymyositis, there is an increase in pro-inflammatory cytokines, especially IL-1β. This
pro-inflammatory cytokine was mainly expressed by macrophages and fibroblasts within the
muscle. Muscle wasting could be due to the presence of IL-1β and the other pro-inflammatory
cytokines involved with the disease, which may play a major role in the pathogenesis of
polymyositis.
Grabiec et al. (2013) also conducted a study that determined the effects of IL-1β on early
myogenesis of mouse C2C12 cells. A three day treatment of IL-1β increased fusion index and
the rate of protein synthesis as well as levels of myogenin and major histocompatibility complex
(MHC). Grabiec et al. concluded that IL-1β activity was limited to the onset of myoblast fusion
and increased the phosphorylation and expression of p38 kinase, leading to activation of essential
pathways for myogenic differentiation.
Further, psychosocial stress within the body, stress resulting from a perceived threat, can
lead to altered immune function and possibly development of psychological disorders. In mice
experiencing repeated social defeats, there was an increase in IL-1β concentrations (Wohleb et

12

al., 2001). Anxiety like behavior was associated with activation of the IL-1 receptor. Therefore,
stress and psychological disorders, such as anxiety and depression, may be related to an increase
concentration of IL-1β which can lead to muscle wasting or necrosis, as shown by previous
studies.

Conclusion
IL-1β is a pro-inflammatory cytokine that is present during inflammation and hinders the
growth of skeletal muscle. Stress and anxiety increase the concentrations of IL-1β, however how
IL-1β affects myoblast function is not well known. The presence of IL-1β may inhibit
myogenesis by altering myoblast proliferation and/or differentiation, decreasing muscle growth.
Therefore, the objective of this study was to determine how IL-1β affects proliferation,
differentiation, and myotube diameter. We hypothesized that IL-1β would decrease myoblast
proliferation and/or differentiation.
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Materials and Methods
Cell Culture
C2C12 myoblasts were cultured in growth media (high glucose Dulbecco's Modified
Eagle Medium [DMEM], 10% Fetal Bovine Serum [FBS], 1% penicillan/streptomycin, and
0.2% gentomyosin) at 37° C in 5% CO2 on gelatin coated culture dishes. Cells were thawed and
cultured for at least one passage before experiments were started.

Cells were passaged when

they were approximately 70% confluent. Cell number was determined using a hemocytometer
and cells were plated at 1x105 cells/cm2 to start the next passage.
Proliferation
To evaluate the effect of IL-1β on proliferation, C2C12 myoblasts were plated at 2.6x103
cells/cm2 on a 12-well culture dish and cultured for 48 hours in the presence of 0.1 ng/mL IL-1β,
1.0 ng/mL IL-1β or carrier only (control). Triplicate wells were treated for each treatment and
the experiment was replicated three times. Cells were pulsed with eoxyuridine (EdU) using the
Click-iT EdU Imaging Kit (Invitrogen). Cells were fixed in 4% formaldehyde in PBS for 15
minutes and immunostained following the manufacturer’s protocol. Nuclei were visualized using
Hoeschst 33342. Images were obtained using the Zeiss Observer Z1 Microscope, taking four
images per well for a total of 12 images per treatment. The number of EdU positive cells was
quantified and is presented as a percent of total nuclei.
Myoblast fusion
To evaluate the effect of IL-1β on myoblast fusion, C2C12 myoblasts were plated at
2.0x104 cells/cm2 on a 12-well culture dish in growth media for 48 hours. Media was changed to
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differentiation media (2% horse serum [HS], 1% penicillin/streptomycin, 0.2% gentomyosin in
low glucose DMEM) supplemented with 0.1 ng/mL or 1/0 ng/mL IL-1β, or carrier only for an
additional 48 hours. Cells were fixed using 4% formaldehyde in PBS for 15 minutes and placed
in blocking solution (Superblock containing 5% HS, 5% bovine serum albumin [BSA]) for 40
minutes. The cells were washed once with PBS and incubated in anti-myosin heavy chain
(MyHC, Developmental Studies Hybridoma Bank, Iowa City, IA) supernatant for 1 hour at room
temperature. The cells were washed with PBS three times and incubated with AlexFluor488
goat α-mouse secondary antibody (1:250) and Hoescht 33342 (1:500) in blocking solution for
one hour in the dark at room temperature. Following extensive washes with PBS, cells were
imaged using the Zeiss Observer Z1 microscope. The fusion index was determined by
quantifying the number of nuclei within multinucleated MyHC-expressing myotubes divided by
total nuclei.
Myotube diameter
To evaluate the effect of IL-1β on myotube diameter, C2C12 myoblasts were plated at
2.0x104 cells/cm2 on 12-well plates in growth media for 48 hours until confluent. Media was
changed to differentiation media for 48 hours to allow formation of myotubes. Myotubes were
cultured for an additional 48 hours in differentiation media supplemented with 0.1 ng/mL or 1.0
ng/mL IL-1β, or carrier only. Cells were fixed and immunostained for MyHC as described
above. Myotube diameter was measured at three distinct places on each MyHC-expressing
multinucleated fiber and used to calculate an average diameter for each myotube.
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Statistics
Data was analyzed using ANOVA in GraphPad Prism followed by Tukey’s test for
multiple comparisons. Data is presented as mean ± SEM. P < 0.05 is considered significant.
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Results
Proliferation
The concentrations of 0.1 and 1.0 ng of IL-1β had no effect on proliferation of C2C12 mouse
myoblasts (Figures 1 and 2; P > 0.05).

Differentiation
The fusion index was decreased by 13.5% when C2C12 mouse myoblasts were treated with 1.0
ng of IL-1β (Figures 3 and 4; P < 0.05). However, there was no difference in the fusion index
between myoblasts treated with 0.1 ng of IL-1β and controls (Figures 3 and 4; P > 0.05).

Myotube diameter
The concentrations of 0.1 or 1.0 ng of IL-1β had no effect on myotube diameter of C2C12 mouse
myoblasts (Figures 5 and 6; P > 0.05).
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Figure 1. C2C12 mouse myoblasts proliferate in the presence of IL-1β. C2C12s were
cultured in low glucose growth media in the presence of 0.1 or 1.0 ng/mL Il-1β or carrier only
for 24 h. Cells were pulsed with eoxyuridine (green), fixed, and immunostained. Nuclei were
visualized with Hoechst 33342 (blue). The two images were then merged. Representative
images shown.
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Relative Proliferation

myoblasts. The
he percent of total
Figure 2. IL-1β does not alter proliferation of C2C12 mouse myoblasts
nuclei positive for EdU was calculated in C2C12s treated with 0 (CON),, 0.1, or 1.0 ng/mL IL-1β.
IL
The data is presented as means ± SEM relative to control. n=3
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Figure 3. C2C12 mouse myoblasts differentiate in the presence of IL-1β. Confluent C2C12
myoblasts were placed in differentiation media containing 0.1 or 1.0 ng/mL IL-1β or carrier only
for 48 h. Myotubes were immunostained for Myosin Heavy Chain [MyHC] (green) and Hoechst
33342 (blue). The two images were then merged. Representative images shown.
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Relative Fusion Index

Figure 4. IL-1β decreases fusion of C2C12 mouse myoblasts. C2C12 myoblasts were treated
with 0.1 ng/mL or 1.0 ng/mL of IL
IL-1β or carrier only (CON). The fusion index was calculated by
quantifying the number of nuclei within multi
multi-nucleated
nucleated myofibers divided by total nuclei and is
presented relative to control as m
mean ± SEM. * P < 0.05, n=3
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Figure 5. Myotube diameter of C2C12 mouse myoblasts in the presence of IL-1β. Myotubes
were cultured for 48 h in differentiation media and then cultured for 48 h with 0.1 or 1.0 ng/mL
IL-1β. Cells were immunostained for Myosin Heavy Chain (MyHC, green) and Hoechst 33342
(blue). The images were then merged. Representative images shown.
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Figure 6. IL-1β does not alter myotube diameter of C2C12 mouse myoblasts. Myotubes were
cultured for 48 h in differentiation media and then cultured for 48 h with 0.1 or 1.0 ng/mL IL-1β.
IL
Myotube
yotube diameter was measured at 3 places on each multinucleated fiberr and then averaged.
Data are presented as mean ± SEM. CON=control, n=3
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Discussion
The data showed that 1.0 ng/mL of IL-1β decreases fusion index by 13.5% while
proliferation and myotube diameter was not affected. Thus, IL-1β may contribute to poor muscle
growth and/or regeneration by decreasing the fusion of myoblasts into existing myofibers. It was
surprising to see that IL-1β only affected fusion index, and not myotube diameter. We
hypothesized that IL-1β would decrease fusion index and myotube diameter, since if myotubes
can’t differentiate properly, then most likely they would not be able to grow properly. However,
IL-1β didn’t affect myotube hypertrophy, just how well they were able to fuse into fibers.
Since stress increases the production of IL-1β (Wohleb et al., 2001), stress may
contribute to poor muscle growth. Plasma concentrations of IL-1β were increased in mice that
had experienced stress, and this could potentially correlate with other animals such as livestock.
Livestock experience many different types of stress such as transportation, changes in the
environment or disease within their environment on a regular basis. This consistent stress could
contribute to a decrease in muscle growth within the animals, leading to a decrease in muscle
mass. This could lead to decreased production, which increases costs to producers and
consumers.
Additionally, patients with inflammatory diseases associated with muscle weakness
exhibit increases in IL-1β (Grundtman et al., 2007). While no direct correlation was drawn
between the muscle weakness and the increase in IL-1β, the authors suggest that IL-1β could
play a major factor in the muscle weakness of these diseases. Since IL-1β decreases
differentiation, this could lead to decreased muscle growth and muscle weakness, supporting the
findings of Grundtman et al. (2007). Further, Spate and Schulze (2004) showed that cancer
increased IL-1β concentrations, increased muscle atrophy, and increased inflammatory cells
24

within the skeletal muscle. Therefore, this muscle wasting could be due to the inflammatory
cells producing more IL-1β, inhibiting differentiation of the myofibers.
However, a study conducted by Grabiec et al. (2013) contradicted this study. When
C2C12 cells were treated for three days with IL-1β, fusion index was increased. They did treat
the cells with the same concentration as this current study, but measured cyclin A and B1 as well
as MyHC and myogenin which weren’t measured within the current study. Therefore, the length
of time treated could have caused the difference in results, but there could have been other
confounding variables throughout the experiments such as the conditions the cells were grown
that could give inconsistent data.
Given this information, future studies could potentially measure the pathways IL-1β
signals through. Inhibiting the JNK and p38 pathways could stop the process of signaling IL-1β,
decreasing the negative effects it has on the body. Overall, this would be able to stop the muscle
wasting due to inflammation or stress resulting in stronger and healthier animals.
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Conclusion
In conclusion, we found neither proliferation nor myotube diameter was affected by
either concentration of IL-1β. However, the fusion index decreased by 13.5% when C2C12
myoblasts were treated with 1.0 ng/mL IL-1β. Thus, IL-1β may contribute to poor muscle
growth and/or regeneration by decreasing the fusion of myoblasts into existing myofibers. Since
stress increases the production of IL-1β, stress may contribute to poor muscle growth through the
cascade involved with the production of IL-1β. This can reduce the overall growth of animals in
the livestock industry. Since livestock experience many different types of stress such as
transportation, changes in the environment, or disease, then this chronic stress could contribute to
a decrease in muscle growth within the animals, decreasing the carcass weight and meat quantity
and quality.
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